This knowledge was applied to clinical treatment in a 2019 study by Liang et al., which found that the irreversible inhibitor afatinib significantly improved progression-free survival and overall survival in patients with lung adenocarcinoma who possessed p.L747P and p.L747S EGFR mutations [93]. The gene discussed is EGFR; the disease is lung adenocarcinoma.